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Abstract
Background: Clinical characteristics and outcomes of intracranial hemorrhage (ICH) among adult patients with
various hematological malignancies are limited.
Methods: A total of 2,574 adult patients diagnosed with hematological malignancies admitted to a single
university hospital were enrolled into this study between 2001 and 2010. The clinical characteristics, image reports
and outcomes were retrospectively analyzed.
Results: A total of 72 patients (48 men and 24 women) with a median age of 56 (range 18 to 86) had an ICH. The
overall ICH incidence was 2.8% among adult patients with hematological malignancies. The incidence of ICH was
higher in acute myeloid leukemia (AML) patients than in patients with other hematological malignancies (6.3% vs
1.1%, P = 0.001). ICH was more common among patients with central nervous system (CNS) involvement of
lymphoma than among patients with CNS involved acute leukemia (P <0.001). Sites of ICH occurrence included the
cerebral cortex (60 patients, 83%), basal ganglia (13 patients, 18%), cerebellum (10 patients, 14%), and brainstem
(5 patients, 7%). A total of 33 patients (46%) had multifocal hemorrhages. In all, 56 patients (77%) had
intraparenchymal hemorrhage, 22 patients (31%) had subdural hemorrhage, 15 patients (21%) had subarachnoid
hemorrhage (SAH), and 3 patients (4%) had epidural hemorrhage. A total of 22 patients had 2 or more types of
ICH. In all, 46 (64%) patients died of ICH within 30 days of diagnosis, irrespective of the type of hematological
malignancy. Multivariate analysis revealed three independent prognostic factors: prolonged prothrombin time
(P = 0.008), SAH (P = 0.021), and multifocal cerebral hemorrhage (P = 0.026).
Conclusions: The incidence of ICH in patients with AML is higher than patients with other hematological
malignancies. But in those with intracranial malignant disease, patients with CNS involved lymphoma were more
prone to ICH than patients with CNS involved acute leukemia. Mortality was similar regardless of the type of
hematological malignancy. Neuroimaging studies of the location and type of ICH could assist with prognosis
prediction for patients with hematological malignancies.
Keywords: central nervous system (CNS) involvement, cerebral hemorrhage, hematological malignancy, prognosis,
neuroimage
Background
In adult patients with hematological malignancies, infec-
tion is the most common complication. Intracranial
hemorrhage (ICH) is the second most common complica-
tion, and is associated with high morbidity and mortality
[1-4]. Several comprehensive reviews have highlighted the
following risk factors for ICH in cancer patients: hyperten-
sion, vessel wall abnormality, invasion or compression of
vessels from a tumor in or adjacent to the brain, low plate-
let count or platelet dysfunction, coagulation factor defi-
ciency, disseminated intravascular coagulation (DIC),
sepsis, and hyperleukocytosis [1,5-8]. Hematological
malignancies comprise a diverse group of neoplasms, and
may directly or indirectly lead to neurological complica-
tions and ICH [9,10]. In recent decades, prophylactic
platelet transfusions to maintain the platelet count at a
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safe threshold have decreased the risk of hemorrhagic
complication [11,12]. However, ICH is still a frequent
complication in patients with hematological malignancies,
and many questions remain unanswered with regard to
the clinical management of ICH in patients with hemato-
logical malignancies.
Patients with lymphoid malignancy more frequently
experience central nervous system (CNS) involvement
than do patients with myeloid leukemia [13,14]. ICH
could be the initial presentation in patients with hemato-
logical malignancies [15,16]. The relationship of ICH and
CNS involvement is still underinvestigated. Evidence on
the clinical manifestations in ICH among the various
hematological malignancies is relatively limited. To clar-
ify the clinical manifestations and prognosis of ICH
among patients with hematological malignancies, we ret-
rospectively reviewed the medical records of patients
admitted to the National Taiwan University Hospital
between 2001 and 2010, and analyzed the data.
Methods
Patients and hospital setting
National Taiwan University Hospital (NTUH) is a 2,600-
bed teaching hospital in northern Taiwan that provides
both primary and tertiary care. We retrospectively ana-
lyzed the demographic features, hematological disease
status, underlying medical diseases, laboratory and
microbiological data, and outcomes of all adult patients
with hematological malignancies from January 2001 to
December 2010 at NTUH. The laboratory data was col-
lected promptly after onset of ICH. We also assessed the
overall 30-day mortality of these patients. This research
conformed to the Helsinki Declaration and local legisla-
tion, and was approved by the National Taiwan Univer-
sity Hospital Research Ethics Committee.
Chemotherapy in patients with hematological
malignancies
Induction chemotherapy consisted of cytarabine and
anthracycline for patients with acute myeloid leukemia
(AML). Consolidation chemotherapy consisted of high-
dose cytarabine-based regimens. Patients with acute pro-
myelocytic leukemia (APL) were treated with all-trans
retinoic acid (ATRA) and combined anthracycline-based
chemotherapy. Patients diagnosed with acute lympho-
blastic leukemia received a Cancer and Leukemia Group
B 8811 (CALGB8811) [17] or Group for Research on
Adult Acute Lymphoblastic Leukemia 2003 (GRAALL
2003) chemotherapy protocol [18]. Patients diagnosed
with lymphoma generally received a chemotherapy regi-
men consisting of CHOP (cyclophosphamide, hydroxy-
daunorubicin (Adriamycin), vincristine (Oncovin), and
prednisolone) with or without rituximab. Lymphoma
patients with CNS involvement received high-dose
methotrexate-based chemotherapy [19]. Patients with
myeloma were treated with thalidomide, or VAD [20]
(vincristine, Adriamycin, and dexamethasone) or DCEP
[21] (dexamethasone, cyclophosphamide, etoposide, and
cisplatin (Platin)) chemotherapy, according to the clini-
cal decision.
Hyperviscosity
Hyperviscosity syndrome is defined by the presence of ele-
vated serum immunoglobulins in conjunction with clinical
constitutional symptoms, bleeding, ocular, neurological,
and cardiovascular manifestations [22].
Policy of platelet transfusion in patients with
hematological malignancy
The platelet counts were checked three times per week
during chemotherapy in patients with hematological
malignancies until the neutrophil counts recovered. The
platelet counts were checked once to three times per
week after neutrophil counts recovered according to clin-
ical judgment. The complete blood counts were checked
once per day in patients with freshly diagnosed acute
promyelocytic leukemia until complete remission. Pro-
phylactic platelet transfusions were used to maintain the
platelet level above 20,000 cells/μl in patients receiving
chemotherapy. Among patients with acute promyelocytic
leukemia, active bleeding, and sepsis, the platelet counts
were maintained above 50,000 cells/μl or more according
to clinical judgment.
Diagnosis of ICH and inclusion/exclusion criteria
Each patient’s ICH diagnosis was determined from both
clinical and neuroimaging findings. Either computed
tomogram or magnetic resonance imaging was required to
confirm the clinical diagnosis of ICH. Patients for whom
ICH was suspected but unproven were excluded. Patients
with ischemic stroke and subsequent hemorrhagic trans-
formation were also excluded. Types and locations of
intracranial hemorrhage were determined from radiology
reports. According to the neuroimaging results, hemor-
rhages were classified into four types, namely intrapar-
enchymal hemorrhage (IPH), subarachnoid hemorrhage
(SAH), subdural hemorrhage (SDH), and epidural hemor-
rhage (EDH) [5].
End points and overall survival
The starting point was the date of diagnosis of ICH. The
primary end point was ICH-related death within 30 days.
Survival time was the time interval from diagnosis of
ICH to events such as death from any cause.
Statistical analysis
For continuous variables, data are reported as the med-
ian with the range shown in brackets. For nominal
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variables, data are reported as the number of patients,
unless specified otherwise. Survival curves were plotted
using Kaplan-Meier analysis, and differences between
curves were analyzed by log rank. All factors in the uni-
variate analyses were also enrolled in multivariate analy-
sis using Cox proportional-hazard testing. All statistical
analyses were performed using SPSS 18.0 for Windows
(SPSS, Chicago, IL, USA), and P values of less than 0.05
were considered statistically significant.
Results
ICH among patients of hematological malignancies
A total of 2,574 adult patients with hematological malig-
nancies were admitted to National Taiwan University
Hospital between 2001 and 2010. During that period,
72 episodes of ICH developed in 72 of these patients
(48 men and 24 women); the median age of the ICH
group was 56 years (range: 18 to 86 years). The ICH
patients included 52 (6.3%) of 818 patients who had AML,
5 (2.0%) of 250 patients with acute lymphoblastic leukemia
(ALL), 7 (0.7%) of 1,001 patients with lymphoma, and
8 (2.7%) of 291 patients with myeloma. Of the 214 patients
who had chronic myeloid leukemia or chronic lymphoid
leukemia, none developed ICH. Our results indicated an
overall ICH incidence of 2.8% among adult patients with
hematological malignancies. Patients with AML displayed
a particularly high incidence of ICH compared with
patients with other hematological malignancies (6.3% vs
1.1%; P = 0.001; odds ratio (OR): 5.89; 95% confidence
interval (CI): 3.49 to 9.93). Except acute promyelocytic leu-
kemia, the incidence of ICH is no different among AML
French-American-British (FAB) subtypes. The clinical
characteristics of ICH in patients with hematological
malignancies are shown in Table 1.
Among the 72 patients with ICH, 46 (64%) had throm-
bocytopenia (platelets less than 20,000 cells/μl), 34 (47%)
had sepsis, and 15 (21%) had prolongation of prothrombin
time. Thrombocytopenia, sepsis and prolongation of pro-
thrombin time are proposed as the potential major causes
of ICH. In all, 28 patients had brain magnetic resonance
angiography to survey the vascular abnormality during
ICH. Neither aneurysm nor arteriovenous malformation
was detected in this study. The clinical characteristics,
including age, sex, hypertension, sepsis, remission status,
and allogeneic stem cell transplantation were not statisti-
cally different among ICH patients with various hematolo-
gical malignancies.
ICH patients who were diagnosed with lymphoma and
myeloma had higher rates of CNS involvement than
patients with other hematological malignancies (P <0.001).
Two of five lymphoma patients with CNS involvement
had been diagnosed with primary CNS lymphoma. One
patient with diffuse large B cell lymphoma and one patient
with primary CNS lymphoma developed ICH before the
start of systemic chemotherapy. The other three lym-
phoma patients who developed ICH during lymphoma
relapsed. One myeloma patient showed immature plasma
cells in the cerebrospinal fluid, but no direct tumor invol-
vement with the CNS. None of the eight myeloma patients
had hyperviscosity syndrome during ICH. L-Asparaginase
was used as a combined chemotherapy protocol in two
ICH patients with ALL, but no statistically significant dif-
ference was found for other clinical manifestations among
ICH patients.
Thrombocytopenia and prolongation of prothrombin
time have been recognized as risk factors for CNS hemor-
rhage in patients with hematological malignancy [2,4]. In
this study, we found patients with prolongation of pro-
thrombin time had a trend towards developing SAH and
significantly higher risk of death (P = 0.008). However, the
platelet count and prothrombin time were not statistically
significantly different among ICH patients with various
hematological malignancies.
Locations and types of ICH
The locations and types of ICH in patients with differ-
ent types of hematological malignancies are shown in
Table 1. ICH locations included the cerebral cortex
(60 patients, 83%), basal ganglia (13 patients, 18%), cere-
bellum (10 patients, 14%), and brainstem (5 patients,
7%). A total of 33 patients (46%) had multifocal hemor-
rhage. Neuroimaging studies revealed that 56 patients
(77%) had IPH, 22 patients (31%) had SDH, 15 patients
(21%) had SAH, and 3 patients (4%) had EDH. In all,
22 patients had 2 or more types of ICH, including
11 patients with IPH and SAH, 6 patients with IPH and
SDH, 1 patient with IPH and EDH, 1 patient with SDH
and SAH, 1 patient with SDH and EDH, and 2 patients
with IPH, SAH, and SDH. Hemorrhage ruptured into
the ventricles (IVH) in 22 patients (31%). EDH occurred
most frequently in patients with myeloma, and neuroi-
maging showed no definite focal lesion in the cranial
vault.
The correlations between clinical characteristics and
types of ICH are shown in Table 2. Younger age was
associated with risk of IPH (P = 0.009), and more
advanced age was associated with SDH (P = 0.002).
Hyperleukocytosis (white blood cell count more than
100,000 cells/μl) showed a trend of being associated with
IPH (P = 0.056). There were 12 patients with hyperleuko-
cytosis at the time of ICH. All 12 patients had IPH (12/
12, 100%). One patient had both IPH and SDH, but no
patients had SAH and EDH.
Correlated clinical manifestation and outcome in patients
with ICH
In total, 25 patients (35%) died within 72 h of the onset
of ICH, and 46 patients (64%) died within 30 days of
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Table 1 Clinical characteristics of intracranial hemorrhage among patients of different types of hematological
malignancies
Number of patients
Subtype AML (n = 43) APL (n = 9) ALL (n = 5) Lymphoma (n = 7) Myeloma (n = 8) P value
Age: 0.094
≥60 years 19 2 1 6 4
<60 years 24 7 4 1 4
Gender: 0.461
Male 32 5 2 4 5
Female 11 4 3 3 3
Underlying hypertension: 0.428
Yes 12 3 0 3 1
No 31 6 5 4 7
Diabetes mellitus: 0.274
Yes 3 1 0 2 0
No 40 8 5 5 8
Sepsis: 0.096
Yes 16 5 5 4 4
No 27 4 0 3 4
Post HSCT: 0.347
Yes 8 0 0 0 1
No 35 9 5 7 7
Disease status: 0.409
Remission 6 2 0 0 0
Active 37 7 5 7 8
CNS involvement: <0.001
Yes 0 0 0 5 1
No 43 9 5 2 7
Leukocyte count: 0.642
≥100,000 cells/μl 9 2 0 1 0
<100,000 cells/μl 34 7 5 6 8
Platelet count: 0.560
≥20,000 cells/μl 27 6 3 6 4
<20,000 cells/μl 16 3 2 1 4
Prothrombin time: 0.493
INR ≥1.5 10 2 1 1 1
INR <1.5 32 7 4 6 7
Location:
Cerebral cortex 37 7 5 4 5 0.326
Basal ganglia 9 1 1 1 1 0.941
Brainstem 4 0 0 1 0 0.628
Cerebellum 4 2 0 1 3 0.213
Multiple 20 5 0 3 5 0.240
Type:
Intraparenchymal hemorrhage 35 7 5 4 5 0.336
Subarachnoid hemorrhage 8 2 2 0 3 0.349
Subdural hemorrhage 11 2 1 4 4 0.307
Epidural hemorrhage 1 0 0 0 2 0.041
Intraventricular hemorrhage 10 4 1 3 2 0.618
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic
stem cell transplantation; INR = international normalized ratio.
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ICH. Mortality was high among patients with EDH (3/
3,100%) and SAH (14/15, 93%), but was relatively lower
in patients with SDH (11/22, 50%). Most patients
received conservative component therapy only, but 11
patients (15%) underwent craniotomy and hematoma
evacuation (6 patients with IPH, 2 patients with SDH,
2 patients with both IPH and SDH, and 1 patient with
SDH and EDH). Seven patients survived for 30 days
(four patients with IPH, two patients with SDH, and one
patient with both IPH and SDH). Five of seven survivors
had long-term survival (more than 1 year) with minimal
neurological sequelae. Surgical intervention showed a
trend of improved 30-day outcome (P = 0.085).
To clarify the clinical manifestations for the 30-day
outcome in patients with hematological malignancies, we
analyzed clinical prognostic factors as shown in Table 3.
Univariate analysis revealed that sepsis (P = 0.05), SAH
(P = 0.007), multifocal cerebral hemorrhage (P = 0.006),
and prolonged prothrombin duration (P = 0.013) were
associated with poor prognosis. The type of hematologi-
cal malignancy had no effect on the 30-day outcome, nor
did allogeneic stem cell transplantation.
All covariates with a P value less than 0.1 were enrolled
in the multivariate analysis. Multivariate analysis was con-
ducted using the Cox proportional hazard test, shown in
Table 3. Poor outcome of ICH in patients with hematolo-
gical malignancies was associated with three independent
factors, namely prolonged prothrombin duration (P =
0.008; OR 10.5; 95% CI 1.3 to 85.5), SAH (P = 0.021; OR
10.9; 95% CI 1.3 to 89.9), and multifocal cerebral hemor-
rhage (P = 0.026; OR 4.7; 95% CI 1.6 to 14.0). Surgical
intervention showed a trend of being associated with
improved prognosis in the univariate analysis (P = 0.085),
but no statistical significance was found for this relation-
ship in the multivariate analysis.
Discussion
The cause of ICH is very important and holds implications
for further therapy. Since no patient received autopsy after
ICH, the definite cause of ICH in patients with hematologi-
cal malignancies is inconclusive. Among the 72 patients
with ICH, 46 (64%) patients had thrombocytopenia (plate-
lets less than 20,000 cells/μl), 34 (47%) had sepsis, and 15
(21%) had prolongation of prothrombin time. Consequently,
Table 2 Clinical characteristics and types of intracranial hemorrhage
IPH (n = 56) P value SDH (n = 22) P value SAH (n = 15) P value
Gender: 0.137 0.180 0.552
Male 40 12 9
Female 16 10 6
Age: 0.009 0.002 >0.999
≥60 years 20 16 7
<60 years 36 6 8
Underlying hypertension: 0.335 0.565 0.324
Yes 13 7 2
No 43 15 13
Sepsis: 0.168 0.306 0.384
Yes 29 8 9
No 27 14 6
Remission status: >0.999 0.421 0.669
Yes 6 1 2
No 50 21 13
CNS involvement: 0.609 0.361 >0.999
Yes 4 3 1
No 52 19 14
Leukocyte count: 0.056 0.090 0.060
≥100,000 cells/μl 12 1 0
<100,000 cells/μl 44 21 15
Platelet count: >0.999 0.603 0.376
≥20,000 cells/μl 36 9 7
<20,000 cells/μl 20 13 8
Prothrombin time: 0.495 0.127 0.069
INR ≥1.5 43 2 6
INR <1.5 13 20 9
CNS = central nervous system; INR = international normalized ratio; IPH = intraparenchymal hemorrhage; SAH = subarachnoid hemorrhage; SDH = subdural
hemorrhage.
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Table 3 Univariate analysis of 30-day outcome of ICH among patients with hematological malignancies.
Alive (n = 26) Dead (n = 46) Univariate analysis, P value Multivariate analysis, P value





≥60 years 12 20






















Subarachnoid hemorrhage 0.007 0.021 (10.9; 1.3 to 88.9)
Yes 1 14
No 25 32







≥100,000 cells/μl 4 8
<100,000 cells/μl 22 38
Platelet count 0.802
≥20,000 cells/μl 16 30
<20,000 cells/μl 10 16
Prolongation of prothrombin time 0.013 0.008 (10.9; 1.3 to 85.5)
INR ≥1.5 1 14
INR <1.5 24 32
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic
stem cell transplantation; ICH = intracranial hemorrhage; INR = international normalized ratio.
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thrombocytopenia, sepsis and prolongation of prothrombin
time are the major predisposing factors for ICH.
The definite causes of ICH could be further investigated
by autopsy study. Occurrence of ICH in patients with
acute leukemia has been reported [3,4]. Case reports of
ICH included patients with primary CNS lymphoma
[23-25], intravascular lymphoma [26,27], and myeloma
[28,29]. However, comparisons of the clinical characteris-
tics and outcome in patients with various hematological
malignancies were limited. The current study reveals that
patients with AML had a higher incidence of ICH than
patients with other hematological malignancies (6.3% vs
1.1%; P = 0.001).
The incidence of ICH is less common in patients with
lymphoma and myeloma, among those with intracranial
involvement. ICH occurred more frequently in patients
with CNS involved lymphoid malignancy relative to those
with CNS involved acute leukemia. The pathogenesis of
ICH among patients with various hematological malignan-
cies may be different. Leukemias are circulating precursors
of lymphoblastic or myeloid neoplasm that involve the
bone marrow and peripheral blood. Leukemias often exert
an indirect effect on the nervous system, causing thrombo-
cytopenia, coagulation factor deficiency, sepsis, therapy-
related complications, and vessel wall abnormalities [9]. In
contrast, for most lymphoma and myeloma patients, the
tumor cells do not invade tissues and vessels. As Glass [9]
proposed, the tumor cells may exert direct effects as solid
tissue tumors on cerebral tissue and blood vessels, result-
ing in vascular occlusion and end-organ ischemia, which
in turn, potentially cause thrombosis and hemorrhagic
transformation. In the current study, we considered that
ICH might partly contribute to the direct invasion or
intravascular involvement of tumor cells in patients with
lymphoma and myeloma, and the definite mechanism of
lymphoma and myeloma associated ICH should be further
investigated.
Patients with CNS lymphoma or myeloma involvement
should be aware of the increased risk of ICH [23-27].
L-Asparaginase is one of the combined chemotherapy
agents frequently used to treat acute lymphoblastic leu-
kemia; it may decrease the plasma antithrombin and
fibrinogen levels, potentially inducing bleeding [30].
Hyperviscosity syndrome and direct tumor invasion also
have been reported, which could lead to fatal ICH in
patients with multiple myelomas [28,29]. L-asparaginase
and myeloma associated hyperviscosity syndrome impli-
cate bleeding tendency, however, both factors did not
disclose the clinical significance of outcome in ICH
patients with hematological malignancies in the current
study
The types and locations of ICH events in patients with
hematological malignancies are also rarely reported
[2,5,31]. A rapid onset of focal neurological deficit with
clinical signs of increased intracranial pressure is
strongly suggestive of a diagnosis of ICH, but cranial
imaging is required to differentiate it from ischemic
stroke [32,33]. In this study, neuroimaging not only dis-
closed the types and locations of ICH, but could also
predict the outcome of patients with ICH. A neuroima-
ging study should be performed rapidly after symptoms
or signs of neurological deficit in patients with hemato-
logical malignancies.
We found most (78%) ICH events in patients with
hematological malignancies tended to be IPH, which was
congruent with prior reports [5,34]. Subdural hemor-
rhage is common among older members of the general
population [35]. Among our study patients with hemato-
logical malignancies, older patients had more SDH than
younger patients (P = 0.002). Symptoms of SDH have a
slower onset than those of ICH, because the lower pres-
sure in veins causes them to bleed more slowly than
arteries [35]. Given that SDH is associated with a rela-
tively good prognosis in patients with hematological
malignancies, clinical awareness of neurological symp-
toms and signs in older patients, and the rapid use of
neuroimaging, could improve diagnostic accuracy and
thus the outcome of ICH. Although SAH represents only
5% of all strokes, it is responsible for 25% of all fatalities
related to stroke in the general population [36].
In the current study, SAH affected only 21% patients
with hematological malignancies but the mortality rate in
the SAH group was 90%. Advances have been made in
surgical intervention for SAH [36], but none of the SAH
patients in the current study received surgery. Surgical
intervention showed a trend of improved 30-day outcome
(P = 0.085) in the current study. Further research or surgi-
cal intervention is needed to improve the prognosis for
SAH patients with hematological malignancies. Hemor-
rhage extending into the ventricles is associated with
obstructive hydrocephalus and a relatively poor prognosis
in ICH of general population [29,37]. Most patients with
hematological malignancies who developed ICH had a
poor prognosis. IVH is not an independent poor prognos-
tic factor in patients with hematological malignancies.
Multivariate analysis using Cox’s proportional hazard
test revealed that ICH in patients with hematological
malignancies was associated with three independent fac-
tors. These were prolonged prothrombin duration (P =
0.008; OR 10.5; 95% CI 1.3 to 85.5), subarachnoid hemor-
rhage (P = 0.021; OR 10.9; 95% CI 1.3 to 89.9), and multi-
focal cerebral hemorrhage (P = 0.026; OR 4.7; 95% CI 1.6
to 14.0). Several studies have demonstrated that prolonga-
tion of prothrombin duration is related to fatal ICH out-
come in patients with hematological malignancies [2-4].
The current study examined prolonged prothrombin dura-
tion as one of the independent prognostic factors for ICH
in patients with hematological malignancies. Leukemic
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cells may express fibrinolysis and other proteolysis
enzymes, which has been implicated in the pathogenesis
of bleeding in some patients [38-40]. Chemotherapy-
related endothelial injury and reduction of coagulation fac-
tors also could play a role in the pathogenesis [38,39].
Coagulopathy in patients with hematological malignancies
could play an important role in the pathogenesis of ICH.
Prolongation of prothrombin time could be ignored dur-
ing the period of chemotherapy of patients with hematolo-
gical malignancies; we suggest regular follow-up of
prothrombin time and prompt correction in patients with
hematological malignancies. This could potentially
decrease the mortality of ICH .
A total of 11 patients underwent craniotomy and
hematoma evacuation. Surgical intervention showed a
trend of improved 30-day outcome (P = 0.085) in ICH
patients with hematological malignancies. Five of the
seven survivors had long-term survival (more than
1 year) with minimal neurological sequelae. Although
few patients underwent surgical intervention, we would
advocate aggressive surgical treatment such as craniot-
omy and hematoma evacuation for those patients with
non-refractory hematological malignancies. Recently,
activated factor VII has been used successfully in patients
with ICH [40-42]. A subsequent phase III clinical trial
revealed that hemostatic therapy with rFVIIa reduced the
growth of hematomas, but did not improve patient survi-
val or functional outcome after intracerebral hemorrhage
[43]. Further clinical trials should be conducted in ICH
patients with hematological malignancies.
There were some limitations to this study. First, we tried
to investigate all the adult patients with hematological
malignancies. However, this study is a retrospective cohort
in a single university hospital between 2001 and 2010.
Given the secular changes in the rapidly evolving field of
hematology, patients may have received different che-
motherapy protocols and supportive management. Second,
thrombocytopenia (64%), sepsis (47%) and prolongation of
prothrombin time (21%) were the most common risk fac-
tors of ICH. However, there was no patient autopsied for
the definite cause of ICH. Furthermore, a prospective mul-
ticenter clinical study should be conducted to define the
incidence of ICH in this population. We limited the defini-
tion of cases to patients with positive neuroimaging study
to prevent confounding factors. Consequently, a few
patients with refractory leukemia and lymphoma who did
not consent to neuroimaging studies were excluded from
this study.
Conclusions
ICH is more common in patients with AML than in
patients with other types of hematological malignancy.
ICH occurred in patients with lymphoma when there
was CNS neoplastic involvement. Prognosis did not
differ according to type of hematological malignancy.
Prolonged prothrombin duration, SAH, and multiple-
site hemorrhage were all independent prognostic factors
of ICH in patients with hematological malignancies.
Neuroimaging studies of the location and type of ICH
could assist with outcome prediction for patients with
hematological malignancies.
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